Sanofi has appointed David Meeker CEO of Genzyme, replacing Henri Termeer, effective 1 November 2011. He will report to Christopher Viehbacher, CEO of Sanofi and chair of Genzyme. Under Mr Meeker's leadership Genzyme plans to incorporate the rare disease business and the multiple sclerosis franchise. Mr Meeker has served at Genzyme since 1994, most recently as COO.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?